This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.

ok
XGEVA (denosumab)

Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional

THE XGEVA® PATIENT

XGEVA® (DENOSUMAB) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SREs) IN ADULTS WITH BONE METASTASES FROM SOLID TUMOURS [SmPC, p. 2]

Adult patients receiving XGEVA® require adequate calcium and vitamin D supplementation (at least 500 mg calcium and 400 IU vitamin D daily). No dose adjustment is necessary in adult patients with renal impairment or in the elderly, and while XGEVA® has not been studied in adult patients with hepatic impairment, the drug is not eliminated by hepatic metabolism.[SmPC, pp. 2, 13]

Adult patients on XGEVA® should be advised to report any symptoms of hypocalcaemia to their treating doctor. Any pain in the groin or hip region may represent atypical femoral fractures and should prompt patients to seek medical advice. Patients should maintain good oral hygiene and be educated on the symptoms of osteonecrosis of the jaw (ONJ). XGEVA® should not be used concomitantly with other products containing XGEVA®.[SmPC, pp. 4-5]